2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14334
    SAM-315 744218-85-7 98%
    SAM-315 (WAY-255315) is a potent antagonist of 5-Hydroxytryptamine-6, with Ki and IC50 of 1.1 nM and 4.6 nM, respectively. SAM-315 significantly increases acetylcholine and glutamate release in hippocampus of the brain.
    SAM-315
  • HY-14335
    Ro 04-6790 202466-68-0 98%
    Ro 04-6790 is a potent, competitive and selective 5-HT6 receptor antagonist with pKi values of 7.26, 7.35 for rat and human 5-HT6 receptors, respectively. Ro 04-6790 has no affinity at other receptors.
    Ro 04-6790
  • HY-14337
    MS 245 263384-65-2 98%
    MS 245 is an antagonist of the 5-HT6 receptor wih an Ki value of 1.5 nM.
    MS 245
  • HY-14356
    ADL5859 850305-06-5 98%
    ADL-5859 is a selective and orally active δ opioid receptor (DOR) agonist with an Ki and an EC50 value of 0.84 and 20 nM, respectively. ADL-5859 also shows inhibitory activity to hERG channel with an IC50 value of 78 μM. ADL-5859 can be used for the research of pain.
    ADL5859
  • HY-14405
    Casopitant 414910-27-3 98%
    Casopitant (GW679769) is a potent, selective, brain-penetrant and orally active neurokinin 1 (NK1) receptor antagonist. Casopitant antagonizes the emetic effects of Substance P (HY-P0201). Casopitant is also a substrate and weak to moderate inhibitor of CYP3A4. Casopitant is indicated for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
    Casopitant
  • HY-14408
    Lu AA47070 913842-25-8 98%
    Lu AA47070 is a phosphonooxymethylene prodrug of a potent and selective Adenosine A2A receptor antagonist. Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade.
    Lu AA47070
  • HY-14442
    ML 10302 hydrochloride 186826-17-5 98%
    ML 10302 hydrochloride is a potent and selective 5-HT4 receptor agonist, with an EC50 of 4 nM. ML 10302 hydrochloride displays more than 680-fold selectivity over 5-HT3 receptor in binding assay.
    ML 10302 hydrochloride
  • HY-14451
    PF-4778574 1219633-99-4 98%
    PF-4778574 is a positive allosteric modulation of AMPA receptor with EC50 of 45 to 919 nM in differenct cells.
    PF-4778574
  • HY-14485
    Ro-51 1050670-85-3 98%
    Ro-51 is a potent and selective dual P2X3/P2X2/3 antagonist, with IC50 of 2 nM and 5 nM for P2X3 and P2X2/3, respectively. Ro-51 can be used for the research for pain.
    Ro-51
  • HY-14517
    H3R antagonist 5 879368-27-1 98%
    H3R antagonist 5 (Compound 1b) is a selective histamine H3 receptor inverse agonist with a IC50 of 0.54 nM and the ability to cross the blood-brain barrier. H3R antagonist 5 can be used in central nervous system-related research.
    H3R antagonist 5
  • HY-14535
    SEN-1269 956128-01-1 98%
    SEN-1269 is a potent Aβ aggregation inhibitor. SEN-1269 blocks Aβ(1-42) aggregation and protects neuronal cell lines exposed to Aβ(1-42). SEN-1269 reduces the deficits in LTP and memory induced by Aβ oligomers. SEN-1269 can be used for the research of Alzheimer's disease.
    SEN-1269
  • HY-14547
    Bifeprunox 350992-10-8 98%
    Bifeprunox is a potent dopamine D2-like and 5-HT1A receptor partial agonist with pKis of 7.19 and 8.83 for cortex 5-HT1A and striatum D2, and a pEC50 of 6.37 for hippocampus 5-HT1A, respectively. Bifeprunox is an antipsychotic for the research of schizophrenia.
    Bifeprunox
  • HY-14554
    Pomaglumetad methionil anhydrous 635318-55-7 98%
    Pomaglumetad methionil anhydrous (LY2140023) is an orally active, methionine prodrug of the selective mGlu2/3 receptor agonist LY404039. LY2140023 has the potential for schizophrenia research.
    Pomaglumetad methionil anhydrous
  • HY-14560
    Reboxetine 71620-89-8 98%
    Reboxetine is an orally active, potent and selective noradrenaline uptake blocker. Reboxetine can be used for antidepressant research.
    Reboxetine
  • HY-14565
    Pozanicline 161417-03-4 98%
    Pozanicline (ABT-089) selectively activate neuronal nicotinic acetylcholine receptor (nAChR) subtypes, is a novel cholinergic agent that is a partial agonist at α4β2* nAChRs (Ki=16 nM) and shows high selectivity for α6β2* and α4α5β2 nAChR subtypes, the binding affinity (Ki, rat) for Pozanicline to [3H] cytisine sites is 16.7 nM. Pozanicline reverses nicotine withdrawal-induced cognitive deficits, may be an effective component of novel therapeutic strategies for nicotine addiction.
    Pozanicline
  • HY-14568
    DCCCyB 1236046-15-3 98%
    DCCCyB is an orally bioavailable, potent, and selective inhibitor of GlyT1. DCCCyB demonstrates excellent in vivo occupancy of GlyT1 transporters in rhesus monkey.
    DCCCyB
  • HY-14575
    Nastorazepide hemicalcium 343326-69-2 98%
    Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain.
    Nastorazepide hemicalcium
  • HY-14578
    Taxiresinol 40951-69-7 98%
    Taxiresinol is an orally active and potent lignan, that can be isolated from the heartwood of Taxus baccata. Taxiresinol shows significant antinociceptive activity.
    Taxiresinol
  • HY-14690
    Ecopipam 112108-01-7 98%
    Ecopipam (SCH 39166) is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam can be used for the research of schizophrenia and obesity.
    Ecopipam
  • HY-14750
    Rabeximod 872178-65-9 98%
    Rabeximod (ROB-803), an anti-rheumatic compound, impairs the differentiation and function of human pro-inflammatory dendritic cells and macrophages via downregulating TLR2 and TLR4 stimulation. Rabeximod (ROB-803) is used for rheumatoid arthritis (RA) research.
    Rabeximod
Cat. No. Product Name / Synonyms Application Reactivity